Análisis costo-beneficio de metodologías para el dosaje de dexametasona fosfato solución oftálmica y sulfametoxazol- trimetoprima suspensión oral
No Thumbnail Available
Date
2021
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidad Nacional de Trujillo
Abstract
El análisis costo-beneficio de las metodologías para dosaje de los medicamentos dexametasona fosfato solución oftálmica y sulfametoxazol-trimetoprima suspensión oral, realizada sobre los sistemas cromatográficos de la farmacopea americana vigente y el desarrollo a UHPLC obtienen reducción tanto los tiempos de uso de equipo de un 53% para dexametasona fosfato solución oftálmica con 25% en reducción global y un 33% para sulfametoxazol-trimetoprima suspensión oral con 13% en reducción global, manteniendo en ambos casos el tiempo de análisis sin variaciones; también demostró una reducción en los costos de reactivos y columna cromatográfica del 10% y 34,4% respectivamente para dexametasona fosfato solución oftálmica y 33% y 4,1% respectivamente para sulfametoxazol-trimetoprima suspensión oral, tanto como el aumento en la durabilidad de columnas cromatográficas, siendo los métodos desarrollados a UHPLC, beneficioso y menos costoso para su implementación.
ABSTRACT The cost-benefit analysis of the methodologies for dosing the drugs dexamethasone phosphate ophthalmic solution and sulfamethoxazole-trimethoprim oral suspension, carried out on the chromatographic systems of the current American pharmacopoeia and the development to UHPLC requesting reduction of both the times of use of a 53% for dexamethasone phosphate ophthalmic solution with 25% overall reduction and 33% for sulfamethoxazole-trimethoprim oral suspension with 13% overall reduction, maintaining in both cases the analysis time without variations; also demonstrated a reduction in reagent and column chromatographic costs of 10% and 34.4% respectively for dexamethasone phosphate solution ophthalmic and 33% and 4.1% respectively for sulfamethoxazole-trimethoprim oral suspension, as well as an increase in the durability of chromatographic columns, being the methods developed to UHPLC, beneficial and less expensive for its implementation.
ABSTRACT The cost-benefit analysis of the methodologies for dosing the drugs dexamethasone phosphate ophthalmic solution and sulfamethoxazole-trimethoprim oral suspension, carried out on the chromatographic systems of the current American pharmacopoeia and the development to UHPLC requesting reduction of both the times of use of a 53% for dexamethasone phosphate ophthalmic solution with 25% overall reduction and 33% for sulfamethoxazole-trimethoprim oral suspension with 13% overall reduction, maintaining in both cases the analysis time without variations; also demonstrated a reduction in reagent and column chromatographic costs of 10% and 34.4% respectively for dexamethasone phosphate solution ophthalmic and 33% and 4.1% respectively for sulfamethoxazole-trimethoprim oral suspension, as well as an increase in the durability of chromatographic columns, being the methods developed to UHPLC, beneficial and less expensive for its implementation.
Description
Keywords
Dexametasona. Sulfametoxazol. Trimetoprima. HPLC. UHPLC